Background {#Sec1}
==========

'Syndromic' patients frequently suffer from recurrent respiratory infections; it is a major cause of morbidity and mortality in this patient group. However, in these patients immunological work-up is often not performed because an immunodeficiency is not suspected. The infections are often ascribed to food and saliva aspiration \[[@CR1]\], structural abnormalities of the upper respiratory tract, neuromuscular problems, malnutrition or institutionalization. Besides, other problems are often more prominent than the recurrent infections. This may lead to underdiagnosis of 'syndromic immunodeficiency'. However, identification of an underlying immune defect may be therapeutically actionable, which in turn may improve the quality of life in these patients: for instance hypogammaglobulinemia can be treated with immunoglobulin replacement \[[@CR2], [@CR3]\]. In addition, information regarding genes critical for the development and functioning of the immune system may be gained by analyzing the precise chromosomal defect and the concomitant immunological phenotype.

Several primary immunodeficiency (PID) disorders have been identified and increasingly their genetic backgrounds have been unraveled \[[@CR4]\]. Syndromes with chromosomal abnormalities of number or structure are considered as a distinct group within PID \[[@CR5]\]. Clear examples are Down syndrome (trisomy 21) \[[@CR6]\] and DiGeorge syndrome (22q11 deletion) \[[@CR7]\]. Also, Turner syndrome \[[@CR8]\] and Wolf-Hirschhorn syndrome \[[@CR9]\] are known to be associated with immunodeficiency. In the past ten years, thirteen cases, three patient series and two families with other chromosomal aberrations and immunological abnormalities have been described in the literature \[[@CR10]--[@CR27]\]. There is one study that screened patients with dysmorphic disorders for immune defects. They showed a high incidence of immunodeficiency in this population (23 out of 29 patients had one or more defects); however, they also included 11 patients with Down syndrome \[[@CR28]\]. We hypothesize that in patients with chromosomal aberrations, other than the well-known Down and DiGeorge syndromes, concomitant 'syndromic' immunodeficiency may be underdiagnosed. To unequivocally prove this, a large case--control study would be needed; this is not really feasible. To explore this further, we performed a retrospective, observational survey study.

Methods {#Sec2}
=======

An email message with the proposal to participate in a survey study was sent out to all members of the European Society for Immunodeficiencies (ESID) to identify as many patients known to ESID members as possible with a chromosomal aberration in combination with one or more identified immunological abnormalities relating to PID. Exclusion criteria were trisomy 21 (Down syndrome) and 22q11 deletion (DiGeorge syndrome), because the immunological abnormalities in these syndromes have been described in detail before \[[@CR6], [@CR7]\]. Those ESID members who agreed to participate in the study were requested to complete an online questionnaire for each of their eligible patients (Additional file [1](#MOESM1){ref-type="media"}). The patients were identified by physician recall. The answers to the questionnaires were encrypted and saved on a protected server; these data did not contain any information that enabled identification of the identity of the patients. Clinical characteristics and identified immunological abnormalities were reported. Age-matched reference values were used for interpretation of immunoglobulin levels and lymphocyte subpopulation counts; values below the age-matched reference values were scored as 'low' \[[@CR29]--[@CR31]\]. For the interpretation of the vaccine responses (i.e. before and after diagnostic vaccination with Tetanus and PneumoVax® or Pneumo(vax)23®) reference values from the laboratory performing the tests were used. For responses to Pneumovax® or Pneumo(vax)23® measured by serotype, a titer ≥1 IU/ml per serotype was considered to be a sufficient response. If only total IgG for S. pneumoniae was tested, a \>4 fold increase of titer was considered as a positive response. Additional immunological tests were performed judged necessary by the treating physician and are therefore only available for some patients. Lymphocyte function tests included in vitro T lymphocyte proliferation tests (to Concanavalin A (ConA), phytohaemagglutinin (PHA), pokeweed mitogen (PWD) and Staphylococcus aureus enterotoxin A (SAE)), natural killer (NK) cell and cytotoxic T cell toxicity (in vitro stimulated CD107a degranulation). Granulocyte function tests included oxidative burst, the quantitative nitroblue tetrazolium dye reduction (NBT) test and phagocytosis test (cells Escherichia coli opsonised). For these additional immunological test (e.g. lymphocyte and granulocyte function tests), the laboratory-specific reference values were used. Furthermore, we asked all the participating centers to provide us with the number of patients with chromosomal aberrations who had undergone an immunological evaluation but were subsequently found *not* to have an immunological abnormality. This was also based on physician recall. Descriptive statistics were performed. The International System for Human Cytogenetic Nomenclature 2013 (ISCN) was used for cytogenetic nomenclature \[[@CR32]\]; an overview is given as a group, and in relation to the specific chromosomal aberrations concerned. The Medical Ethical Committee Brabant approved of the study procedures.

Results {#Sec3}
=======

Fifty-two patients from 16 different centers distributed globally were reported. Six patients had to be excluded because they did not meet the inclusion criteria: 3 patients did not have a confirmed chromosomal aberration, 1 patient with Rubinstein-Taybi Syndrome (no chromosomal aberration, only single gene mutation), 1 patient with suspected Kabuki Syndrome (no genetic diagnosis) and 1 patient with Rothmund-Thomson Syndrome (no chromosomal aberration, only single gene mutation). Three other patients did not have an immunodeficiency, these were 3 related patients with familial t (12;14). An overview of the excluded patients is presented in Additional file [2](#MOESM2){ref-type="media"}.

The 46 included patients consisted of 24 males and 22 females with a median age of 10.4 years at the moment of reporting (range 1.0--69.2 years; 36 pediatric and 10 adult patients). Two families were reported: patients 17 and 20 are related, as well as patients 18 and 19 (they are also related to the excluded patients 2, 3 and 4, see Additional file [2](#MOESM2){ref-type="media"}). Fifteen of these 46 included patients have been published before and publication of two patients is currently in press (for details see Table [1](#Tab1){ref-type="table"}).Table 1Clinical characteristics of the included patientsNrSexAge (yrs)^1^GeneticsImmunological presentation^2^Other clinical presentations^3^Other symptoms1M15.246, XY, dup(6) (p12.2p21.31)AirwaysDevelopmental delay\
Dysmorphic features\
MicrocephalyPrematurity 36 weeks\
Tracheostomy\
Feeding difficulties\
Infantile pyloric stenosis\
Pulmonary congestion\
Intractable diarrhoea2^(a)^M3.446, XY.ish der(16)t(16;19) (p13.3;p13.3) arr\[hg19\] 16p13.3(106 271--1 024 153)x1, 19p13.3 (327 273--6 887 622)x3Failure to thriveDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Microcephaly\
Growth retardationBilateral inguinal hernia\
Horse shoe kidney\
Hypospadia, hydrocele\
Maldescensus testis3^(a)^M9.446, XY.ish der(14)t(14;19) (p11.2;p13.2) de novo; arr\[hg19\] 19p13.3p13.2(90 897--7 300 043)x3Unusual infectionsDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Microcephaly\
Growth retardationBilateral incarcerated inguinal hernia\
Congenital hip dysplasia\
Perineal hypospadia/penoscrotal fistula\
Severe osteopenia\
Sensorineurinal hearing loss\
Epilepsy4M5.646, XY, del(18) (p11.2)AirwaysAtaxia, paresis or other motor disability\
Growth retardationna5M12.047, XY, +13AirwaysDevelopmental delay\
Growth retardationSepsis\
Seizures\
Gastroesophageal reflux disease\
Loss of vision6F6.146, XX, del(16) (p11.2)AirwaysDevelopmental delay\
Dysmorphic featuresObesity\
Autism\
BCGosis7M5.146, XY, del(2) (q33.2)AI diseaseDevelopmental delay\
Dysmorphic featuresCleft palate\
PDA\
Splenomegaly\
Auto-immune hemolytic anemia8M1.0No full karyotype available\
Array CGH : gain of 144kB in 9p24.3 and loss of 15MB in 10q26.11.q26.3Unusual infectionsDevelopmental delay\
Dysmorphic features\
Microcephaly\
Growth retardationDuodenal atresia\
PDA\
Micropenis, gonadal agenesia9F5.246, XX, del(18) (q22)AI diseaseDevelopmental delay\
Dysmorphic featuresAuto-immune polyendocrine syndrome type II with:\
Thyroiditis\
Vitiligo\
Pernicious anemia\
Type 1 diabetes mellitus10F1.446, XX, arr\[hg19\] 16p11.2\
(29, 567, 295-30, 177, 916)x1 dnFailure to thriveDevelopmental delay\
Growth retardationRecurrent fever11F69.245, XAirwaysDysmorphic features\
Growth retardationSchwannoma\
Hearing loss12F6.545, X\[[@CR42]\]/47, XXX \[[@CR8]\]AirwaysDevelopmental delay\
Growth retardationCurrarino syndrome13F41.645, XUnusual infectionsGrowth retardationna14M20.146, XY, der(X)t(X;18) (q28;q23)\
(MECP2 duplication)AirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic featuresVitiligo\
Bronchiectasis\
Small intestinal villous atrophy15^(b)^M7.546, XY, r(18)(p11.2q23) \[97\]/45, XY, -18 \[[@CR3]\]AirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Microcephaly\
Growth retardationASD II, VSD\
Micropenis16^(c)^F47.7arr\[hg19\] 11q24.2q25\
(126, 074, 297-134, 927, 114)x1AirwaysDevelopmental delay\
Dysmorphic features\
Atopic eczemaVSD\
Infertility\
HPV associated giant condylomata\
Hypothyroid\
Idiopathic angio-edema\
Severe asthma\
Hypersplenism\
Obesity, type II diabetes\
Bronchiectasis17^(d)^M22.346, XY, der(18)t(10p;18q) with 18q22.3--q23 deletion and partial trisomy of 10pterAirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Growth retardationHypothyroid (subclinical)\
Pulmonary valve stenosis18^(e)^F29.346, XX, t(12;14) (p11.2;q13)AI diseaseAtopic eczemaSamter\'s triad\*\
ALL\
Migraine\
Recurrent herpes labialis\
HPV associated condylomata\
Multiple allergies19^(e)^F4.946, XX, t(12;14) (p11.2;q13)AirwaysNonena20^(d)^F28.246, XX, der(18)t(10p;18q) with 18q22.3--q23 deletion and partial trisomy of 10pterAirwaysAtaxia, paresis or other motor disability\
Dysmorphic features\
Atopic eczemaThymus hyperplasia\
Atopy\
Polyarticular JIA21F31.346, XX, arr\[hg19\] 15q25.2\
(83, 214, 012-84, 776, 990)x1AirwaysNoneAllergy\
Epilepsy\
Asthma\
Cholesteatoma\
Recurrent monoarthritis22M34.346, XY, inv(10)(q21q23)AI diseaseNoneAsymptomatic23^(f)^F6.946, XX, del(19)(p13.13)AirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Microcephaly\
Growth retardationIUGR\
Epilepsy24^(f)^M9.646, XY, r(18)AI diseaseDevelopmental delay\
Dysmorphic features\
Growth retardation\
HypopigmentationPanniculitis with lipodystrophy\
Auto-immune hypothyroidism\
Vitiligo\
Chronic urticaria\
Subaortic stenosis25^(g)^M16.846, XY, der(11)dup(11) (q22q23)del(q24.3)AirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Atopic eczema\
Hair and/or nail abnormalitiesna26M3.7No full karyotype available\
arr\[hg19\]11p12-p11.12 (38.090.281-49.257.082)x1AirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic featuresDefective absorption folinic acid27F10.346, XX, del(11)(q11)Failure to thriveDevelopmental delay\
Dysmorphic features\
Growth retardation\
Atopic eczemana28F5.949, XXXXXPyogenic infectionsDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic featuresPS and ASD\
Hypermobility\
Radio-ulnar synosthosis29M15.146, XY.ish del(X) (p11.3p11.3)\
(RP4-628F15+, RP11-245M24 dim, RP6-99M1-, RP4-689N3-, RP11-1409+)matFailure to thriveDevelopmental delay\
Microcephaly\
Growth retardationVisual impairment\
Retinitis pigmentosa30M9.446, XY, r(6)AirwaysDevelopmental delay\
Dysmorphic features\
Microcephaly\
Growth retardationGastro-oesofageal reflux\
Dilated cardiomyopathy and small VSD31^(h)^F12.846, XX, del(18)(p11.1)AirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Growth retardationType I diabetes mellitus\
Growth hormone deficiency\
Autoimmune thyroiditis\
Pectus excavatum\
Retrognathia with absent maxillary chondyles32M6.846, XY, del(7)(q22.3 q31.3)AirwaysDevelopmental delay\
Dysmorphic featuresna33F14.747, XX, +der(22)t(11;22) (q23;q11) mat (partial trisomy 11q)AirwaysDevelopmental delay\
Ataxia, paresis or other motor disabilityPalatoschizis, preauricular tags\
Anus atresia\
Urolithiasis34F7.946, XX.arr snp 2p23.1 (SNP_A-2078092-\>SNP_A-2248377)x1 matSame pathogenDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic featuresMitochondrial dysfunction\
Acracyanosis\
Bronchiectasis\
Hyposplenia35M11.346, XY.arr\[hg19\] 3p14.3 (57, 994, 310-58, 071, 249)x1 patAirwaysDevelopmental delay\
Dysmorphic featuresSubmucosal palatal schisis\
Transient neonatal macroglossi\
Hepatosplenomegaly36F6.845, XAirwaysNonena37F20.246, XX, der(2)t(2;10)(q37.3;q26.3)mat.arr snp 2q37.2q37.3(SNP_A-1957498-\>SNP_A-2027809)x1,10q26.3 (SNP_A-2264115-\>SNP_A-1934598)x3AirwaysDevelopmental delay\
Ataxia, paresis or other motor disabilityAutistiform developmental delay\
Splenomegaly\
Cytopenias\
Granulomata\
Gastroparesis\
Obesitas38^(i)^M6.549, XXXXYAirwaysDevelopmental delay\
Dysmorphic featuresna39^(i)^M10.649, XXXXYAirwaysDevelopmental delay\
Dysmorphic featuresna40^(i)^M14.649, XXXXYAirwaysNonena41^(i)^M13.349, XXXXYAirwaysDevelopmental delay\
Dysmorphic featuresna42^(i)^M11.749, XXXXYAirwaysDevelopmental delay\
Dysmorphic features\
Atopic eczemana43M12.247, XYY, dup(22) (q11.21)Pyogenic infectionsDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
MicrocephalyAsthma44F3.846, XX.arr snp 1q44 (SNP_A-2136114-\>SNP_A-4223408)x1 dn, 11p11.2p11.12 (SNP_A-1817808-\>SNP_A-4198132)x3 patAirwaysDevelopmental delay\
Dysmorphic features\
Microcephaly\
Growth retardation\
Atopic eczemaEpilepsy\
Rocker bottom foot\
Cow's milk allergy\
Feeding difficulties45F6.746, X, idic(X) (p11.21).arr snp 22q11.21 (SNP_A-2108791-\>SNP_A-2160861)x3 mat, Xp22.33p11.21(SNP_A-4207883-\>2247707)x1 dn, Xp11.21q28(SNP_A-4201150-\>SNP_A-2267820)x3 dnAirwaysDevelopmental delay\
Growth retardationPrematurity; gestational age 30 weeks\
Bone anchored hearing aid\
Periorbital hemangioma46F12.946, XX, arr cgh 16p13.11p13.12\
(14, 687, 636-16, 452, 200) x3.AirwaysDevelopmental delay\
Ataxia, paresis or other motor disability\
Dysmorphic features\
Microcephaly\
Growth retardation\
Atopic eczemaSevere scoliosis\
Seizures\
Myopathy of unknown etiology\
Chronic progressive external ophthalmoplegia\
Contractures; wheelchair boundHeadings: Nr = patient number; ^1^at the time of reporting; ^2^most prominent clinical immunological presentation; ^3^other clinical presentations as requested in the survey (Additional file [1](#MOESM1){ref-type="media"})Patients: (a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254--263, (b) previously published in Celmeli F, et al. J Investig Allergol Clin Immunol. 2014;24(6):442--4, (c) previously published in Seppänen et al. J Clin Immunol 2014;34:114--118., (d) family members and previously published in Dostal et al. International Journal of Immu-genetics 2007;34: 143--147 : patient 17 as IV:4 and patient 20 as IV, (e) family members, together with excluded patient 2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San Jose C, J Paediatr Child Health 2011;47(7):485--6, (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263--266, (i) previously published in Keller MD, et al. Am J Med Genet C Semin Med Genet. 2013;163C(1):50--4Clinical presentations: Airways = Recurrent ENT and airway infections; FTT = failure to thrive from early infancy; unusual infections = unusual infections or unusually severe course of infections; AI disease = autoimmune or chronic inflammatory disease, lymphoproliferation; pyogenic infections = recurrent pyogenic infections; same pathogen = recurrent infections with the same type of pathogen (de Vries E. Clin Exp Immunol 2012;167(1):108--19.)Other abbrevations: *ALL* acute lymphatic leukemia, *ASD* atrial septum defect, *BCG* Bacillus Calmette-Guérin, *F* female, *HPV* human papilloma virus, *IUGR* intra uterine growth retardation, *JIA* juvenile idiopathic arthritis, *M* male, *na* not available, *PDA* patent ductus arteriosus, *PEG* percutaneous endoscopic gastrostomy, *PS* pulmonary stenosis, *VSD* ventricular septum defect, yrs: years\* Samter's triad: asthma, aspirin and NSAID sensitivity, and nasal/ethmoidal polyposis

Seven out of the total 16 centers provided the number of patients with chromosomal aberrations who had undergone an immunological evaluation but were subsequently found *not* to have an immunological abnormality. Together, they reported 27 patients with immunological abnormalities in this survey; they also reported 63 patients with chromosomal aberrations in whom immunological assessment revealed no abnormality. Thus, of these centers 30 % of the patients with chromosomal aberrations who underwent immunological evaluation were diagnosed with some form of primary immunodeficiency.

Symptoms indicative of PID can be divided into eight different clinical presentations \[[@CR29]\]; 'recurrent ear-nose-throat (ENT) and airway infections' were most commonly reported in this cohort (in 43/46 patients). In 31/46 patients, 'recurrent ENT and airway infections' was reported as the clinically most important presentation. Other PID-related manifestations reported as the most important clinical presentation include 'auto-immune or chronic inflammatory disease; lymphoproliferation'(*n* = 5); 'failure to thrive from early infancy' (*n* = 4); 'unusual infections or unusually severe course of infections'(*n* = 3); 'recurrent pyogenic infections' (*n* = 2) and 'recurrent infections with the same type of pathogen'(*n* = 1). The most common syndromic-related manifestations were: developmental delay (*n* = 37), ataxia, paresis or other motor disability (*n* = 16), dysmorphic features (*n* = 31), microcephaly (*n* = 11), growth retardation (*n* = 19), atopic eczema (*n* = 8), hair and/or nail abnormalities (*n* = 1) and hypopigmentation (*n* = 1). A detailed overview of the clinical findings is shown in Table [1](#Tab1){ref-type="table"}.

Antibody deficiency was the most common immunological defect identified. Of 33 patients reported to have low immunoglobulin isotype(s), 20 had low IgG (Fig. [1](#Fig1){ref-type="fig"}). Nine patients had low IgG with completely absent IgA and 8 patients had low IgG in combination with low IgM. IgG subclass deficiency was identified in 18 patients, of which 15 had concomitant low total immunoglobulin isotype(s) and 3 did not. Vaccine responses were tested in 32/46 patients and were found insufficient in 18 patients: 16/18 were insufficient for pneumococcal polysaccharide vaccine. Four patients (no. 2, 22, 23 and 24) showed normal antibody production after diagnostic vaccination despite low serum immunoglobulins. For patients 23 and 24, however, the decreased response was based on total IgG for S. pneumoniae. Responses to live vaccines were not documented; no unfavorable outcomes of natural chickenpox infection were reported. 18/46 patients were treated with immunoglobulin replacement. The indication of immunoglobulin replacement therapy was based on clinical grounds, as judged by the treating physician. In 2 patients lymphopenia was reported; one of them was neutropenic as well. Lymphocyte subpopulations (CD3, CD4, CD8, CD19 and CD16/56) were determined in 36 patients; in 16 a decreased count of ≥1 (sub)populations was reported. In 11 patients more extensive B cell subpopulations were determined and in 7 patients extensive T cell subpopulations (protocols differed per patient). In 1 patient total absence of B lymphocytes was reported (patient number 5; trisomy 13). Lymphocyte and granulocyte function tests were performed in 11 and 11 patients, respectively; in 2 decreased lymphocyte as well as granulocyte function was reported (patients 2 and 3). A detailed overview of the immunological and other laboratory findings is presented in Table [2](#Tab2){ref-type="table"} and Additional file [3](#MOESM3){ref-type="media"}.Fig. 1Levels of immunoglobulin isotypes. Every dot represents a patient. The bold black line is the lower limit of normal according to age-matched reference values (ref de Vries E. Clin Exp Immunol 2012;167(1):108--19.). **a**: IgG in g/L. **b**: IgA in g/L; two values \> 2.0 g/l are not displayed in the graph. **c**: IgM in g/LTable 2Results of immunological and other diagnostic tests in the included patients. A: Immunological screening testsNrNPLP↓G↓A↓M↓IgG subclassLymphocyte subsetsResp TVResp PL functionG function1\--++^\*^-na↑ aCD3, ↑ aCD3CD4↓↓nana2^(a)^\--+-++IgG1, IgG3↓ aCD3, ↓ a smBnlnl↓ NK toxicityOxidative burst borderline ↓In vitro lymphocyte proliferation: nl3^(a)^\-\-\-\-\--Borderline ↓ a smBnlnl↓ vitro lymphocyte proliferation decreased from 7 years on: SEAModerate ↓ oxidative burst4\-\--+-nanananlnana5\--++^\*^++IgG1, IgG2, IgG3Absence of CD19 cellsnanaIn vitro lymphocyte proliferation: nlna6\-\--+^\*^\--↑ aCD3, ↑ aCD3CD4, ↑ aCD19nlnlnanl7\-\--+^\*^-na↓ aCD3, ↓ aCD3CD8 ↓ aCD19↓nanana8\--++^\*^-nanlnananana9\-\-\-\-\--↑ aCD16/56↓nanlna10\-\-\-\--na↑ aCD3, ↑ aCD19, ↑ aCD16/56nlnaThymic function: nlna11\--+\--na↓ aCD3CD8, ↓ aCD19, ↑ aCD16/56nanlnanl12\--++-na↑ aCD3, ↑ aCD3CD4, ↑ aCD19nlnanana13+++\--na↓ aCD3CD4, ↓ aCD19, ↓ aCD16/56, ↑ aCD3CD8nananana14\-\--+++IgG2, IgG4nlna↓^(j)^nana15^(b)^\-\-\--+-nlnananlnl16^(c)^\--++-+IgG1, IgG2, IgG4↓ aCD3, ↓ aCD3CD4, ↓ aCD19, ↓ aCD16/56nananana17^(d)^\-\--+^\*^-+^\*\*^IgG2, IgG4nlnananana18^(e)^\--+\--+IgG1, IgG2, IgG4↓ aCD19, ↓ aCD16/56nananana19^(e)^\--++^\*^-+IgG1nanananana20^(d)^\-\--+^\*^-+IgG4↓ aCD16/56nananana21\-\-\-\--+IgG3, IgG4↓ aCD19 cells, slightly ↓ aMZ-like B, ↑ aCD3, ↑ aCD3CD8nlnlnlna22-++++-↓ aCD3, ↓ aCD3CD4, ↓ aCD3CD8, ↓aCD19 cells (BM)nlnlnana23^(f)^\--++-+IgG1, IgG2, IgG4↓ aCD3CD4, ↓ aCD16/56nlnl^(j)^↓ In vitro lymphocyte proliferation: PHA = 85 %, PWD = 72 %, ConA = 39 %na24^(f)^\--++^\*^-+^\*\*\*^IgG2, IgG3, IgG4↓ aCD3CD8nlnl^(j)^↓ In vitro lymphocyte proliferation: PHA = 92 %, PWD = 87 %, ConA = 28 %na25^(g)^\--+++nananl↓↓ In vitro lymphocyte proliferation: PHAna26\--+-++IgG1, IgG3nana↓nana27\-\-\-\-\--↓ aCD3, ↓ aCD3CD4, ↓ aCD3CD8, ↓ aCD19, ↓ aCD16/56↓↓↓ In vitro lymphocyte proliferation: PHAna28\-\--++na↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8, ↑ aCD19nlnlnanl29\-\-\-\-\--↑ aCD3CD8, ↑ aCD19nl↓nanl30\-\-\--+na↓ aCD3, ↓ aCD3CD8 cells, ↑ aCD19nl↓nanl31^(h)^\-\--+-+IgG2↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8, ↑ aCD19nl↓nanl32\-\--++na↑ aCD19nlnlnanl33\-\-\-\--+IgG1nananlnana34\-\-\-\-\--nlna↓nanl35\-\--+-+IgG2nlna↓nana36\--++-nananananana37\--++++IgG1, IgG2↓ aCD3, ↓ aCD3CD8, ↓ aCD19, ↓ aCD16/56 cells, ↓ a memBnananana38^(i)^\--+\--nanana↓nana39^(i)^\--nananana↑ aCD3CD4na↓nana40^(i)^\-\-\-\--na↑ aCD3, ↑ aCD3CD4na↓nana41^(i)^\-\-\-\--nanana↓nana42^(i)^\-\-\-\-\--↑ aCD3, ↑ aCD3CD4, ↑ aCD19, ↑ aCD16/56na↓nana43\--++-+IgG2↑ aCD3, ↑ aCD3CD4, ↑ aCD3CD8, ↑ aCD 19nl↓nana44\-\-\-\--+IgG1nanananana45\-\--+\--nanananana46\--+++nanlnanananaHeadings: *Nr* patient number, *NP* neutropenia, *LP* lymphopenia,↓*G*: low IgG,↓A: low IgA,↓M: low IgM.↓IgG subclass: low IgG subclasses, *Resp TV* response tetanus vaccine, *Resp P* response PneumoVax® or Pneumo23®, L function: lymphocyte function tests, G function: granulocyte function testsPatients: (a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254--263, (b) previously published in Celmeli F, J Investig Allergol Clin Immunol. 2014;24(6):442--4, (c) previously published in Seppänen et al. J Clin Immunol 2014;34:114--118., (d) family members and previously published in Dostal et al. International Journal of Immu-genetics 2007;34: 143--147 : patient 17 as IV:4 and patient 20 as IV, (e) family members, together with excluded patient 2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San Jose C, J Paediatr Child Health 2011;47(7):485--6. (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263--266, (i) previously published in Keller MD, et al. Am J Med Genet C Semin Med Genet. 2013;163C(1):50--4, (j) decreased response to Pneumovax ® or Pneumo23® based on total IgG for S. pneumoniae^\*^ IgA completely absent, ^\*\*^ IgG2 completely absent, ^\*\*\*^IgG3 completely absentOther abbrevations: *a* absolute cell count, *BM* bone marrow, *CD* cluster of differentiation, *ConA* Concanavalin A, *memB* memory B cells, *MZ* marginal zone, *na* not available, *nl* normal, *PHA* phytohaemagglutinin, *PWD* pokeweed mitogen, *SEA* Staphylococcus aureus enterotoxin A, *smB* switched memory B cells

Discussion {#Sec4}
==========

Our call identified 46 patients with chromosomal aberration associated with immunodeficiency, the largest cohort reported in the literature so far (42 isolated cases, and twice 2 patients from the same family). Based on data from 7/16 participating centers, up to one third of patients with chromosomal aberrations and recurrent infections may have some form of primary immunodeficiency. Because the patients in this study were identified by physician recall, reporter bias is possible. However, the relative number is much higher than the 6 % found in a cohort of 259 'normal' children screened for immunological abnormalities because of recurrent infections by Brodszki et al. \[[@CR33]\]. The most common clinical presentation in our cohort was *'*recurrent ENT and airway infections*'*, which triggered their physician to perform immunological investigations. Not surprisingly, these were mostly 'predominantly antibody deficiencies' \[[@CR34]\] ranging from IgG-subclass deficiency and/or polysaccharide antibody deficiency to severe hypogammaglobulinemia or even agammaglobulinemia in one patient. While this study may have limitations inherent to a retrospective, observational survey (e.g. recall bias; reporting bias; convenience sampling), these findings suggest that \'syndromic immunodeficiency' may be under-diagnosed.

A previous study in patients with dysmorphic features found low CD19^+^ and CD16^+^ and/or CD56^+^ cells as the most frequent immunological abnormalities, followed by low immunoglobulins \[[@CR28]\]. However, in contrast to our survey this study also included a lot of patients with Down syndrome (11/29 patients) who are known to have lower CD19^+^ and CD3^−^CD16^+^ and/or CD56^+^ cells \[[@CR6]\], precluding an appreciation for the possibility of underlying immunodeficiency in patients with non-Down, chromosomal syndromes. Until now, no other cohorts of patients with different chromosomal aberrations associated with immunological abnormalities have been described. The chromosomal aberrations described in our study may provide insight regarding novel genes involved in the immune system, either located directly within or adjacent to the anomalous loci. Several of the cytogenetic abnormalities in our patients have been linked to immunodeficiency or -dysregulation in the literature before.

The largest family in our cohort consists of 5 affected patients with 46, XX, t (12;14) (p11.2;q13) (patients 18, 19 and excluded patients 2, 3 and 4). Only two had immunodeficiency (patients 18 and 19), both with low IgG-levels and one with additional IgA-deficiency and decreased numbers of CD19^+^ and CD3^−^CD16^+^and/orCD56^+^ cells. All patients in this family suffered from atopy, asthma and/or allergy (some with anaphylaxis); two developed acute lymphatic leukemia. A candidate gene located on chromosome 14q13 is *nuclear factor of kappa light chain gene enhancer in B cells inhibitor alpha (NFKBIA)* (OMIM 164008). NFKBIA inactivates NF-kappa-B by trapping it in the cytoplasm. Functional impairment of NFKBIA can result in increased activation of the NF-kappa-B pathway leading to immune dysregulation \[[@CR35]\].

The other family in our cohort consists of two cousins with an unbalanced translocation t (18q;10p), namely t (18q-;10p+) (patients 17 and 20), effectively resulting in a 18q22.3--q23 deletion and a partial trisomy of 10pter. Both showed IgA-deficiency and IgG-subclass deficiency (both IgG4 and one also IgG2), and one showed decreased numbers of CD3^−^CD16^+^and/or CD56^+^ cells. One of the cousins showed diffuse thymic hyperplasia (patient 20) without evidence of developing thymoma. Although patients with complete 10p trisomy are not reported to have immunodeficiency \[[@CR36], [@CR37]\], patients with terminal deletions of 10p have been reported with IgA- and IgG-deficiency before \[[@CR21], [@CR38]\]. The 18q − syndrome is associated with IgA-deficiency and other autoimmune or immunodeficiency diseases, such as common variable immunodeficiency (CVID) \[[@CR39]\], juvenile rheumatic arthritis \[[@CR40]\], insulin-dependent diabetes mellitus \[[@CR41]\], celiac disease \[[@CR42]\] and thyroid hormone abnormalities \[[@CR43]\]. This partly matches the clinical phenotypes of our related patients. The other patients in our cohort with chromosome 18q aberrations all but one also showed IgA-deficiency (patients 9, 14, and 20). The two cousins from our study are part of a Finnish family with t (18q;10p), which was published in 2007 \[[@CR20]\]. All members of this family showed IgA-deficiency; IgG-subclasses were not tested in the other family members. The authors hypothesized that the observed IgA-deficiency may result from haplo-insufficiency of one or multiple genes located in the 18q22.3--q23 region in possible connection with a larger polygenic network.

Our cohort contains two patients with ring chromosome 18 (one mosaic (patient 15) and one with complete chromosome 18 deletion (patient 24)) and one patient with 18p deletion (patient 31). Deletions of chromosome 18p have also been associated with immune-related dysfunction like autoimmune thyroiditis, diabetes mellitus, IgA deficiency, atopic skin conditions, juvenile rheumatoid arthritis \[[@CR12], [@CR15], [@CR22], [@CR25]\], and in one patient with SLE \[[@CR12]\]. This matches with our patients: two patients had an IgA-deficiency and the patient with 18p deletion had multiple endocrine dysfunctions. However, our patient with a mosaic form of ring chromosome 18 (46, XY, r(18) (p11.2q23) \[97\]/45, XY, -18 \[[@CR3]\], patient 15) showed only low IgM with recurrent respiratory tract infections, as published before \[[@CR27]\].

Four of our patients showed chromosome 11q deletions (patients 16, 25, 27 and 33); two of them were published before \[[@CR14], [@CR26]\]. Terminal deletion of chromosome 11 can cause Jacobsen syndrome \[[@CR44]\] and has previously been associated with hypogammaglobulinemia, pancytopenia and low T-helper cell counts \[[@CR45], [@CR46]\]. Our patients with 11q deletion did not show neutropenia or lymphopenia, but three of them had both IgG- and IgA-deficiency. No low T-helper cell counts were reported.

Two centers reported a patient with deletion of chromosome 16p11.2 (patients 6 and 10). Deletions in this region of chromosome 16 are associated with intellectual disability, congenital anomalies, obesity, macrocephaly, and autism \[[@CR47]\]. This matches the clinical picture of one of our patients. Both patients showed only minor immunological abnormalities: IgA deficiency and global lymphocytosis. Recently, single nucleotide polymorphisms at the fused-in-sarcoma (FUS)/integrin CD11b (ITGAM) locus at 16p11.2 were associated with CVID phenotypes \[[@CR48]\]. In the literature, there is also a report of an autistic girl with a 16p11.2 deletion who also had severe combined immunodeficiency (SCID) caused by Coronin-1A deficiency (also located at 16p11.2) \[[@CR49]\]. Coronin-1A is essential for development of a normal peripheral T cell compartment in mice as well as men \[[@CR33], [@CR50]\]. However, this girl had, in contrast to our patient, next to the 16p11.2 deletion, also a 2 bp deletion of the Coronin-1A gene on the other (paternal) allele.

Several patients with X-chromosome aberration were included. Turner syndrome (45, X) is known to be associated with immunodeficiency \[[@CR5], [@CR8]\], but with different clinical presentations. Our four Turner patients (patients 11, 13 and 36, and patient 12 with mosaicism Turner) also showed a variety of immunological abnormalities. The relationship, if any, between the immune defects in Turner syndrome and those in established X-linked PID remains unknown. Additionally, 5 boys with 49, XXXXY (patients 38, 39, 40, 41 and 42) and 1 girl with 49, XXXXX (patient 28) were reported. The 49, XXXXX girl presented with pyogenic infections and low IgG and IgM levels, but with normal granulocyte levels and function. The 49, XXXXY boys all presented with 'recurrent ENT and airway infections', and they all showed impaired antibody responses to pneumococcal polysaccharide antigens, as was published before \[[@CR11]\].

Conclusion {#Sec5}
==========

This retrospective survey demonstrates that patients with chromosomal aberrations and recurrent infections may harbor underlying primary immunodeficiencies. By specifically excluding the syndromic immunodeficiencies associated with Down and DiGeorge syndromes, we showed that a diverse spectrum of chromosomal aberrations can be associated with immunological abnormalities. In our cohort antibody deficiency was the most prevalent; this is important because infectious complications can be prevented with early interventions like antibiotic prophylaxis or immunoglobulin replacement treatment in these patients. To assess whether this association is a truly causal relation, a large case--control study would be needed; this is not really feasible. And of course, our survey results do not negate other contributing factors (e.g. aspiration; abnormal anatomy) in the development of recurrent ENT and airway infections in these patients. Nonetheless, our findings suggest it is important to consider immunological investigations in patients with chromosomal aberration and recurrent infections.
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